JANE CHUNG, R.Ph.
President & Chief Operating Officer
“Our unique technology and extensive discovery and development toolkit of antibodies, linkers, and payloads enable us to reimagine every aspect of ADC design in our mission to deliver transformative medicines and benefit to patients.”
Jane Chung, RPh has over 20 years of pharmaceutical and biotechnology experience and serves as our President and Chief Operating Officer since December 2023 and previously our Chief Commercial Officer since August 2021. From 2015 to 2021, Ms. Chung served in several leadership roles at AstraZeneca, including as President and General Manager of AstraZeneca Canada, Vice President of Sales and Marketing of U.S. lmmuno-Oncology, and Senior Commercial Business Director. Prior to that, from 2013 to 2015, Ms. Chung served as a Regional Sales Director and Director of Sales Productivity and Effectiveness for Onyx Pharmaceuticals Inc. From 2003 to 2013, she served in various commercial roles for Genentech, Inc., including as Commercial Operations Manager, Division Manager and Senior Marketing Manager. Ms. Chung also serves on the Board of Directors of Viracta Therapeutics, Inc. and on non-profit boards in the science, education, and community development arenas. Ms. Chung received her B.A. from Columbia University, New York, and B.S. in Pharmacy from St. John’s University, New York.
